Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland

@inproceedings{Lebioda2014RelevanceOI,
  title={Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland},
  author={Andrea Lebioda and David Gasche and Franz-Werner Dippel and Karlheinz Theobald and Stefan Plant{\"o}r},
  booktitle={Health economics review},
  year={2014}
}
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA). In case no head-to-head studies are available for direct comparisons, the submission of indirect comparisons is permitted to assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG) states a clear… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS